Navigation Links
PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
Date:9/26/2008

act to fund the continued development of our third generation rPA anthrax vaccine program. This latest contract is in addition to an earlier NIH contract for up to $6.9 million, which was awarded in 2005," commented David P. Wright, President and Chief Executive Officer. "PharmAthene has built a diversified, best-in-class portfolio of novel biodefense product candidates and we view this latest award as a direct validation of our technology as well as a reaffirmation of the U.S. government's commitment to the development and procurement of next generation medical countermeasure solutions."

Mr. Wright added, "Based on development efforts to date, PharmAthene's third generation vaccine could offer significant improvements in both stability and storage compared to the current FDA approved vaccine, thereby meeting the government's requirements for civilian deployment in the Strategic National Stockpile. By comparison, the currently available anthrax vaccine, BioThrax(R) Anthrax Vaccine Adsorbed, which was initially licensed by the Food and Drug Administration in 1970, requires six doses over a period of eighteen months to achieve protective immunity and is required to be stored at between 2 degrees Celsius and 8 degrees Celsius."

PharmAthene believes that the third generation rPA anthrax vaccine contract is part of a broader strategy by the Department of Health and Human Services to ensure that the Strategic National Stockpile (SNS) contains the most efficacious anthrax medical countermeasures currently available. Near-term, the Company believes second generation rPA anthrax vaccine will gradually replace the currently licensed vaccine. Longer-term, third generation rPA vaccine -- with substantial improvements in stability and storage requirements -- will be the procurement option of choice.

Mr. Wright continued, "PharmAthene is strategically building a leading franchise in anthrax countermeasures - a potential billion dollar market. This includes no
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
2. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
5. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
6. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
7. PharmAthene Reports First Quarter 2008 Financial Results
8. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
9. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
10. PharmAthene Reports Year-End 2007 Financial Results
11. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- New interactive learning forums will ... of the medical device industry at the 2013 ... from June 18-20 in Philadelphia ... ) , These all-new MedTech Innovate ... presentations and implementable solutions on the most cutting-edge ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... Brea, CA (PRWEB) May 17, 2013 IAC ... DisperSol Technologies, a start up laboratory needing to set up ... be moving to a larger facility within a year’s time. ... the knowledge that the laboratory is temporary? What is efficient ... 4 Series modular workstations from IAC Industries. The planners at ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... CellCyte Genetics,Corporation (the "Company") (OTC Bulletin Board: CCYG) ... develop, manufacture and market its patented,line of stem ... is developing stem cell enabling therapeutic products,designed to ... adult stem cells to diseased organs, such as ...
... Expand Versatility of DelSite cGMP Polymer, ... (Pink Sheets: CARN) today announced its wholly-owned,subsidiary, ... rights license agreement with a biotechnology company ... DelSite,s,high-molecular-weight anionic polysaccharide which is produced under ...
... Sept. 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), a ... Pharmaceutical Co., Ltd (Kelun), China,s largest producer of,intravenous ... financial highlights with respect to the consolidated results ... interest entity,(Kelun Group) for the first half of ...
Cached Biology Technology:CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 2CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 3CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 4Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 2Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5
(Date:5/16/2013)... MA -- Injectable nanoparticles developed at MIT may ... 1 diabetes to constantly monitor their blood-sugar levels ... were designed to sense glucose levels in the ... of insulin, thereby replacing the function of pancreatic ... Type 1 diabetes. Ultimately, this type of system ...
(Date:5/16/2013)... an ancient extinct creature with ,scissor hand-like, claws in ... his favourite movie star. , The 505 million ... Koo-ten-ee-che-la depp-eye), which is a distant ancestor of lobsters ... for his starring role as Edward Scissorhands - a ... creation, who has scissors for hands. , ...
(Date:5/16/2013)... Cameroon and the manager of San Diego Zoo Global,s ... Whitley award. The Whitley award is an international ... it celebrates the extraordinary achievements of some of the ... was selected for the award due to his efforts ... its wildlife inhabitants., HRH The Princess Royal, the charity,s ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Actor Johnny Depp immortalized in ancient fossil find 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... and WEST PALM BEACH, Fla. , May ... authentication and endpoint protection solutions and ScriptRx, a leading ... Systems for Emergency Rooms and Urgent Care Centers, today ... into the ScriptRx System. Designed for these busy clinical ...
... A research appearing in Nature , with ... from the Department of Genetics and Microbiology at UAB, ... virulent genes causing infections. The research describes an unprecedented ... of treating and preventing bacterial infections. , Pathogenic ...
... transport through shipping, income from tourism and recreation ... is a challenge that calls for reframing humans as ... of Europe,s leading marine organisations in a new report ... Board-European Science Foundation (ESF), the International Council for the ...
Cached Biology News:ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 3ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 4Surprising infection inducing mechanism found in bacteria 2Sustainable use of our seas needs an integrated view of humans and nature 2
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
...
Request Info...
Penicillin-Streptomycin liquid...
Biology Products: